Stryker (NYSE:SYK) Price Target Cut to $365.00 by Analysts at Barclays

Stryker (NYSE:SYK) had its price objective lowered by Barclays from $375.00 to $365.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical technology company’s stock.

A number of other research firms have also recently issued reports on SYK. Evercore set a $350.00 price objective on Stryker in a research report on Monday, July 6th. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price for the company. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Thursday. Finally, Johnson Rice cut shares of Stryker to a “hold” rating in a research note on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $355.84.

Stryker Stock Down 6.5%

SYK opened at $291.56 on Friday. The firm has a market cap of $111.83 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business has a 50 day moving average price of $292.83 and a 200 day moving average price of $324.51. Stryker has a twelve month low of $267.00 and a twelve month high of $389.33.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The business had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.83%. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.19 earnings per share. Research analysts forecast that Stryker will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a dividend of $0.88 per share. The ex-dividend date was Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is presently 36.48%.

Insiders Place Their Bets

In related news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SYK. Community Bank & Trust Waco Texas raised its holdings in Stryker by 2.3% in the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after buying an additional 31 shares during the last quarter. Cornerstone Financial Management LLC boosted its position in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the period. NWF Advisory Services Inc. grew its holdings in Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock worth $463,000 after acquiring an additional 33 shares during the last quarter. Harold Davidson & Associates Inc. grew its holdings in Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after acquiring an additional 34 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC increased its position in Stryker by 0.9% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock valued at $1,236,000 after acquiring an additional 34 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.